Please select your page
  • Slide
  • Slide
  • Slide

Audit committee

CERENIS christian chavyChristian Chavy
President of the Audit committee, Chief Executive Officer of Stallergenes

Christian Chavy brings substantial pharma and biotech management experience to the Board. Mr. Chavy is currently CEO and Board member of MedDay Pharmaceuticals. From 2014 to March 2016, he was Chief Executive Officer of Stallergenes. In 2010, Mr. Chavy joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals. Prior to joining Actelion, he was Vice President at Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY has graduated from ESSEC and from the Institut de Contrôle de Gestion of Paris (ICG).


CERENIS Richard PASTERNAKRichard Pasternak, M.D.
Member of the Audit committee, Chairman

Dr. Pasternak has had a long-standing research interest in lipid disorders and atherosclerosis, as well as patterns of practice and disease management and prevention. Previously, he was Vice President, Head of Cardiovascular Clinical Research and Head of Global Scientific Affairs and Scientific Leadership at Merck & Co from 2004 and 2010. Prior to this, he was Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital from 1992 to 2004, and he was Associate Professor of Medicine at the Harvard Medical School.
Dr. Pasternak has authored more than 100 publications and has spoken widely on the development of drugs for the treatment of cardiovascular diseases, and about how academia and industry can better collaborate in biomedical research. He is currently a faculty member of the Weill Cornell School of Medicine, and serves on the Boards of the Founder’s Affiliate of the American Heart Association, the Galien Foundation, and Essentialis Therapeutics.



B.Yanni 10 14sq

Barbara Yanni, JD, MA, BA
Member of the Audit committee, Independent Administrator 

Barbara Yanni has over thirty years of experience in pharmaceutical Business Development and Finance. Barbara currently serves as an independent director of three clinical-stage biopharmaceutical companies: Trevena (NASDAQ:TRVN), Symic Bio and Vaccinex (NASDAQ: VCNX). She serves on the audit committee of all three companies and chairs Trevena’s compensation committee.

Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Merck’s Vice President and Chief Licensing Officer. Barbara and her team successfully structured and negotiated agreements to acquire rights to over 150 compounds, programs and technologies to enhance Merck's pipeline. Barbara greatly increased Merck's visibility as a preferred partner – Merck was named "best biopharma partner" in an independent survey by Boston Consulting Group.

Barbara began her Merck career as a tax lawyer and then transitioned to Finance, first as Director of Benefits Financing and subsequently as Senior Director of Financial Evaluations and Analysis where she evaluated the financial aspects of acquisitions, joint ventures, licenses and other transactions. She joined Merck’s corporate development group in 1997. Before joining Merck Barbara was a tax lawyer in New York.  

Barbara has a JD from Stanford Law School and an AB from Wellesley College where she studied Physics and Latin. She also holds a Masters of Law in Taxation from New York University.



Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2
31130 Balma – France
Tel. +33 5 62 24 97 06
Fax +33 5 61 57 34 12


Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143